CURE Pharmaceutical Holding Corp. (OTCMKTS:CURR)
We’re looking back in on CURR this morning on the heels of a key PR released by the company that we would like to share with our readers. We have been following this stock for roughly a month, and this FDA IND approval news is by far the most exciting development yet.
CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for its product CUREfilm Blue™, an oral soluble film of sildenafil citrate (the active ingredient present in Viagra®1) for the treatment of erectile dysfunction (ED). CURE is seeking approval of this product via the 505(b)(2) regulatory pathway to expedite the U.S. approval process. (>>View Full PR via OTCMARKETS)
In addition to familiarizing yourself with the company’s news update, we would recommend you take a couple of minutes to check out the video presentation of the CURR chart that we have provided below:
______
Please direct any investor inquiries on CURR to:
Gary Zwetchkenbaum
Plum Tree Consulting LLC
Phone: (718) 224-3123
Cell: (516) 455-7662
Website: www.plumtreeconsultingllc.com
Fresh Options Ideas:
SPY 01/06 $368-367 Puts
Extended Watchlist:
TSPG, WDLF, ISWH, USRM, OZSC, LBRMF